AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HALO · NASDAQ · Biotechnology

Halozyme Therapeutics (HALO)

Enables subcutaneous delivery of partner medicines through ENHANZE technology.

$112.92

vs last close−2.21 (−1.92%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	216	230	196	231	290	298	265	326	354	452	377	481
Cost of revenue	55	52	46	57	49	42	66	64	73	102	109	79
Gross profit	161	178	150	174	241	256	199	262	281	350	268	402
	73	77	54	57	77	80	57	59	63	95	83	114
Research & development	17	21	19	21	18	20	15	18	17	32	26	28
	35	38	35	36	41	42	42	42	46	63	58	57
General & administrative	0	0	0	0	0	0	0	0	0	0	0	57
Other expenses	20	18	0	0	18	18	0	0	0	0	0	30
Operating income	88	101	96	117	163	176	142	202	218	254	185	288
	13	0	0	1	2	3	2	2	1	−355	−4	−3
Interest income	0	0	0	0	0	0	0	7	5	0	1	0
Interest expense	5	5	5	5	5	5	5	4	4	5	6	6
Other non-operating income	−18	−5	−5	−5	−6	−7	−7	−7	−5	350	−1	−3
Income before tax	102	101	96	118	165	178	144	205	219	−101	180	285
Income tax expense	20	16	19	24	28	41	26	40	44	41	30	55
Net income from continuing operations	82	85	77	93	137	137	118	165	175	−142	150	230
Net income	82	85	77	93	137	137	118	165	175	−142	150	230
EPS, basic	$0.62	$0.66	$0.61	$0.73	$1.08	$1.08	$0.96	$1.36	$1.49	−$1.20	$1.27	$1.96
EPS, diluted	$0.61	$0.65	$0.60	$0.72	$1.05	$1.06	$0.93	$1.33	$1.43	−$1.20	$1.22	$1.90
Weighted average shares, basic	132	129	127	127	127	126	123	121	117	118	118	117
Weighted average shares, diluted	134	131	129	129	130	129	127	124	122	118	123	121
EBITDA	129	127	121	143	190	203	169	230	244	−69	220	320
Depreciation & amortization	23	21	20	20	20	20	20	20	20	27	34	30
EBIT	106	106	101	122	170	183	148	209	223	−96	186	290